Edwards Lifesciences Japan — Selling, general, and administrative expenses decreased by 38.1% to $15.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.0%, from $16.40M to $15.90M. Over 3 years (FY 2022 to FY 2025), Japan — Selling, general, and administrative expenses shows relatively stable performance with a 0.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A decrease relative to revenue suggests improved operating leverage, while a significant increase may indicate aggressive investment in market expansion or rising administrative overhead.
This metric aggregates the operating expenses required to support the sales, marketing, and administrative functions spe...
Comparable to regional SG&A allocations in global medical device companies.
ew_segment_japan_selling_general_and_administrative_expenses| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.35M | $19.35M | $19.35M | $19.35M | $17.53M | $17.53M | $17.53M | $17.53M | $26.00M | $19.60M | $17.70M | $21.80M | $16.40M | $18.50M | $17.90M | $25.70M | $15.90M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -9.4% | +0.0% | +0.0% | +0.0% | +48.4% | -24.6% | -9.7% | +23.2% | -24.8% | +12.8% | -3.2% | +43.6% | -38.1% |
| YoY Change | — | — | — | — | -9.4% | -9.4% | -9.4% | -9.4% | +48.4% | +11.8% | +1.0% | +24.4% | -36.9% | -5.6% | +1.1% | +17.9% | -3.0% |